dexlansoprazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiulcer, benzimidazole derivatives	4162	138530-94-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: dexlansoprazole sesquihydrate R-Lansoprazole (R)-Lansoprazole dexlansoprazole kapidex dexilant TAK-390 TAK-390MR	Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production. Molecular weight: 369.36 Formula: C16H14F3N3O2S CLOGP: 2.60 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 67.87 ALOGS: -3.17 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dexlansoprazole sesquihydrate
R-Lansoprazole
(R)-Lansoprazole
dexlansoprazole
kapidex
dexilant
TAK-390
TAK-390MR

Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.

Molecular weight: 369.36
Formula: C16H14F3N3O2S
CLOGP: 2.60
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 67.87
ALOGS: -3.17
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 30, 2009	FDA	TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	1811.49	38.77	287	657	3831	2353310
Acute kidney injury	535.36	38.77	147	797	27975	2329166
Renal injury	485.60	38.77	77	867	900	2356241
End stage renal disease	461.71	38.77	67	877	404	2356737
Renal failure	347.54	38.77	95	849	17254	2339887
Diarrhoea	189.08	38.77	91	853	83473	2273668
Incorrect product administration duration	165.21	38.77	36	908	2459	2354682
Drug ineffective	157.93	38.77	86	858	101538	2255603
Tubulointerstitial nephritis	132.82	38.77	30	914	2408	2354733
Gastrooesophageal reflux disease	106.19	38.77	33	911	9062	2348079
Off label use	80.72	38.77	50	894	73548	2283593
Abdominal pain upper	77.59	38.77	33	911	22067	2335074
Drug hypersensitivity	73.06	38.77	40	904	46603	2310538
No adverse event	72.38	38.77	25	919	9503	2347638
Nausea	63.81	38.77	51	893	112138	2245003
Abdominal distension	55.37	38.77	21	923	10390	2346751
Nephrogenic anaemia	53.28	38.77	9	935	153	2356988
Renal haemangioma	51.12	38.77	6	938	2	2357139
Dyspnoea	49.35	38.77	38	906	78695	2278446
Rebound acid hypersecretion	48.69	38.77	6	938	6	2357135
Abdominal pain	46.93	38.77	27	917	34347	2322794
Muscle spasms	43.59	38.77	22	922	21544	2335597
Dizziness	42.68	38.77	31	913	58634	2298507
Vomiting	41.44	38.77	33	911	71569	2285572
Pruritus	41.15	38.77	27	917	43313	2313828
Anaphylactic reaction	39.01	38.77	16	928	9689	2347452

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	1079.08	54.28	181	324	4136	1742140
End stage renal disease	431.11	54.28	64	441	548	1745728
Acute kidney injury	367.00	54.28	111	394	34833	1711443
Renal injury	317.93	54.28	54	451	1140	1745136
Renal failure	221.76	54.28	67	438	19950	1726326
Gastrooesophageal reflux disease	93.40	54.28	25	480	4622	1741654
Incorrect product administration duration	87.79	54.28	18	487	1037	1745239
Occupational exposure to air contaminants	78.62	54.28	9	496	2	1746274
Occupational dermatitis	66.45	54.28	8	497	7	1746269
Nephrogenic anaemia	65.84	54.28	11	494	200	1746076
Erythema of eyelid	58.70	54.28	10	495	205	1746071

Pharmacologic Action:

Source	Code	Description
ATC	A02BC06	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Proton pump inhibitors
FDA EPC	N0000175525	Proton Pump Inhibitor
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D054328	Proton Pump Inhibitors

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Peptic ulcer	indication	13200003	DOID:750
Erosive esophagitis	indication	40719004
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Maintenance of Healing Erosive Esophagitis	indication
Duodenal ulcer disease	off-label use	51868009	DOID:1724
Zollinger-Ellison syndrome	off-label use	53132006	DOID:0050782
Gastric ulcer	off-label use	397825006	DOID:10808
Duodenal Ulcer due to H. Pylori	off-label use
Maintenance of Healing Duodenal Ulcer	off-label use
NSAID-Induced Gastric Ulcer	off-label use
Prevention of NSAID-Induced Gastric Ulcer	off-label use
Pathological Gastric Hypersecretory Condition	off-label use
Osteoporosis	contraindication	64859006	DOID:11476
Fracture of bone	contraindication	125605004
Hypomagnesemia	contraindication	190855004
Disease of liver	contraindication	235856003	DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.23	acidic
pKa2	3.35	Basic
pKa3	2.72	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6462058	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6939971	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6462058	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6462058	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6939971	June 15, 2020	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6939971	June 15, 2020	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT SOLUTAB	TAKEDA PHARMS USA	N208056	Jan. 26, 2016	DISCN	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE	ORAL	6664276	Jan. 30, 2023	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8784885	Oct. 15, 2023	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	8173158	March 17, 2030	TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	9233103	March 5, 2032	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
60MG	DEXILANT	TAKEDA PHARMS USA	N022287	Jan. 30, 2009	RX	CAPSULE, DELAYED RELEASE	ORAL	9233103	March 5, 2032	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Potassium-transporting ATPase	Transporter	P20648 P51164	ATP4A_HUMAN ATP4B_HUMAN	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4028570	VUID
N0000189452	NUI
C2348248	UMLSCUI
D08903	KEGG_DRUG
442540007	SNOMEDCT_US
26184	MMSL
d07395	MMSL
816346	RXNORM
4028570	VANDF
441863009	SNOMEDCT_US
012953	NDDF
HS2S9VK3NH	UNII
313640-86-7	SECONDARY_CAS_RN
8524	INN_ID
DB05351	DRUGBANK_ID
CHEBI:135931	CHEBI
5487	IUPHAR_LIGAND_ID
CHEMBL1201863	ChEMBL_ID
D064748	MESH_DESCRIPTOR_UI
9578005	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4374	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	19 sections
Kapidex	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5998	CAPSULE, DELAYED RELEASE	30 mg	ORAL	NDA	16 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6152	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	19 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	55154-5154	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	19 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	64764-171	CAPSULE, DELAYED RELEASE	30 mg	ORAL	NDA	19 sections
Dexilant	HUMAN PRESCRIPTION DRUG LABEL	1	64764-175	CAPSULE, DELAYED RELEASE	60 mg	ORAL	NDA	19 sections